Management of Systolic Heart Failure in an Elderly Patient with CKD (GFR 40 ml/min)

This is HFrEF with stage 3b chronic kidney disease — the classic cardiorenal situation in geriatric practice.

CKD is present in nearly one-third of heart failure patients; renal function declines with age and creatinine clearance is often below 60 ml/min in older HF patients.

Renal impairment in HF arises from reduced renal perfusion, renal vasoconstriction, renal venous congestion, and over-diuresis; older people are also less able to excrete excess sodium and water.

Importantly, a GFR of 40 ml/min does not contraindicate disease-modifying therapy — it mandates lower starting doses, slower titration, and closer monitoring.

Confirm the diagnosis with echocardiography and natriuretic peptides, remembering that NT-proBNP is elevated by renal impairment itself and must be interpreted accordingly.

Perform a comprehensive geriatric assessment — frailty, cognition, functional status, polypharmacy, nutrition, and patient preference.

Exclude reversible contributors: renal artery stenosis, obstructive uropathy, NSAIDs, hypovolaemia, and contrast exposure.

Establish baseline creatinine, eGFR, potassium and blood pressure before starting or changing therapy.

ACE inhibitor or ARB — start at low dose (for example enalapril 2.5 mg twice daily) and up-titrate slowly. Even low doses provide benefit if the maximum dose cannot be reached.

Accept a rise in creatinine of up to 30% and a fall in eGFR after initiation — this is haemodynamic, not nephrotoxic, and is not a reason to stop. Beyond 30%, halve the dose and investigate.

Do not combine an ACE inhibitor with an ARB — the combination failed to reduce mortality and carries significant risk of renal impairment, hyperkalaemia and hypotension.

Beta blocker — carvedilol, bisoprolol, nebivolol, or modified-release metoprolol. Beta blockers are not renally limited and are often the best-tolerated pillar in CKD. Start low, go slow.

Mineralocorticoid receptor antagonist — spironolactone or eplerenone. Use with great caution at GFR 40: start 12.5 mg daily, check potassium and creatinine at 1 week, 4 weeks, then periodically. Withhold if potassium >5.0 mEq/l.

ARNI (sacubitril/valsartan) — may replace the ACE inhibitor/ARB; note hyperkalaemia, hypotension and angioedema as adverse effects, and observe the 36-hour washout from any ACE inhibitor.

Diuretics — loop diuretics (furosemide, bumetanide, torsemide) are the mainstay for congestion. Higher doses are needed in CKD because tubular delivery of drug is reduced. Diuretics are less effective in the elderly and increase the risk of electrolyte abnormality.

In diuretic resistance, use intravenous loop diuretic or sequential nephron blockade by adding a thiazide (metolazone) — but this greatly increases the risk of hypokalaemia, hyponatraemia and AKI, and requires close inpatient monitoring.

Ivabradine if still symptomatic in sinus rhythm with heart rate >70/min — it has no renal dose adjustment, making it useful here.

Digoxin — reduce to 0.125 mg daily or alternate days; renal impairment markedly increases toxicity risk. Monitor potassium and levels (target 0.5–0.9 ng/ml).

Hydralazine-isosorbide dinitrate is a useful alternative when RAAS blockade cannot be tolerated because of hyperkalaemia or worsening renal function.

Treat anaemia — common in this group from CKD, poor haematinic intake, and antiplatelet/anticoagulant use. Intravenous iron is safe and effective and improves symptoms, functional capacity and quality of life.

Manage atrial fibrillation with beta blockers (which reduce mortality in AF with HF) and/or digoxin; rhythm control has not proven superior to rate control.

Avoid NSAIDs absolutely — they worsen heart failure, cause AKI, and interfere with ACE inhibitors.

Restrict sodium to about 1500 mg/day and restrict fluid where there is dilutional hyponatraemia. Advise daily weights.

Review the entire drug list at every visit; polypharmacy and drug–drug interactions are the dominant iatrogenic hazards in this population.

Check renal function, electrolytes and blood pressure after every dose change and periodically thereafter. Falls and postural hypotension are the key clinical toxicities to look for.

Device therapy — CRT if QRS >130 ms; ICD only if expected survival exceeds 12 months, weighing comorbidity, frailty, and the ethical issue of eventual deactivation.

Multidisciplinary follow-up with nephrology input and, where trajectory is poor, early advance care planning and palliative care.